Alectinib capsules150mg/capsule, 56 capsules/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Hepatotoxicity: Liver laboratory indicators are monitored every 2 weeks for the first 3 months of treatment, then monthly, and patients with elevated transaminases and bilirubin are examined more frequently as clinically indicated. If ALT, AST, or bilirubin is severely elevated, the dose should be interrupted or reduced, or LuciAle should be permanently discontinued.
• Interstitial lung disease (ILD)/pneumonia: Patients diagnosed with ILD/pneumonia should discontinue LuciAle immediately and permanently if no other potential cause of ILD/pneumonia is identified.
• Renal impairment: Suspend LuciAle in case of severe renal impairment, then resume LuciAle with a reduced dose or permanently discontinue use after recovery.
• Bradycardia: Monitor heart rate and blood pressure regularly. If symptomatic, interrupt LuciAle and then reduce the dose or permanently discontinue.
• Severe myalgia and elevated creatine phosphokinase (CPK): CPK is assessed every two weeks during the first month of treatment and in patients who report unexplained muscle pain, tenderness, or weakness. If the CPK is severely elevated, discontinue use and then decide to resume or reduce the dose after evaluation.
• Hemolytic anemia: discontinue use of LuciAle if hemolytic anemia is suspected. If hemolytic anemia is confirmed, consider resuming or permanently discontinuing a dose reduction after remission.
• Embryo-fetal toxicity: LuciAle can cause harm to the fetus. Inform women of their fertility potential of the potential risks to the fetus and use effective contraception.

Medication risks

Adverse Reactions
The most common adverse reactions (incidence ≥ 20%) are hepatotoxicity, constipation, fatigue, myalgia, edema, rash, and cough.